Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
-
New pill targets advanced cancers in first human tests
Disease control OngoingThis early-stage study is testing a new oral drug called ERAS-601 in adults with advanced solid tumors that have spread. The main goals are to find the safest and most effective dose, both when given alone and when combined with other cancer therapies. Researchers will also check…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New Two-Drug attack targets Tough-to-Treat cancer mutation
Disease control OngoingThis study is testing the safety and early effectiveness of a new drug combination (naporafenib plus trametinib) for people with advanced solid tumors that have a specific genetic change called a RAS Q61X mutation. It is for patients aged 12 and older whose cancer has grown despi…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New drug duo battles Tough-to-Treat skin cancer in major trial
Disease control OngoingThis study is testing whether a new combination of two drugs, naporafenib and trametinib, works better than current standard treatments for people with advanced NRAS-mutant melanoma that has continued to grow after immunotherapy. The trial will compare how long patients live with…
Phase: PHASE3 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC